Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel L Suzman

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2025
FDA Approval Summary: Niraparib Plus Abiraterone Acetate Fixed Dose Combination for BRCA-Mutated Metastatic Castration-Resistant Prostate CancerWilliam F Maguire, Dow-Chung Chi, Sundeep Agrawal, et al.
Cancer Discovery|December 12, 2023
Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug DevelopmentJoshua M Donaldson, Marjilla Seddiq, Michael J Fusco, et al.
The Lancet. Oncology|July 26, 2021
Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trialsJaleh Fallah, Lijun Zhang, Anup Amatya, et al.
Oncotarget|July 10, 2018
Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancerKarim Boudadi, Daniel L Suzman, Valsamo Anagnostou, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 12, 2024
Advancing Clinical Trial Design for Non-Muscle Invasive Bladder CancerElaine Chang, Noah M Hahn, Seth P Lerner, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2025
FDA Approval Summary: Niraparib Plus Abiraterone Acetate Fixed Dose Combination for BRCA-Mutated Metastatic Castration-Resistant Prostate CancerWilliam F Maguire, Dow-Chung Chi, Sundeep Agrawal, et al.
Cancer Discovery|December 12, 2023
Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug DevelopmentJoshua M Donaldson, Marjilla Seddiq, Michael J Fusco, et al.
The Lancet. Oncology|July 26, 2021
Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trialsJaleh Fallah, Lijun Zhang, Anup Amatya, et al.
Oncotarget|July 10, 2018
Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancerKarim Boudadi, Daniel L Suzman, Valsamo Anagnostou, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 12, 2024
Advancing Clinical Trial Design for Non-Muscle Invasive Bladder CancerElaine Chang, Noah M Hahn, Seth P Lerner, et al.
Pageof 5